摘要
目的:探究阿托伐他汀联合美托洛尔治疗冠心病合并心衰的临床疗效。方法:选择2018年12月—2019年11月本院收治的90例冠心病合并心衰患者,随机分为对照组和观察组,各45例。对照组给予阿托伐他汀治疗,观察组在对照组基础上口服美托洛尔,两组均治疗3个月。比较两组临床疗效以及两组治疗前、治疗3个月后甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血浆氨基末端脑钠肽前体(NT-proBNP)水平。结果:治疗后,观察组有效率高于对照组;观察组TC、TG、LDL-C、NT-proBNP低于对照组,HDL-C高于对照组,差异有统计学意义(P<0.05)。结论:阿托伐他汀联合美托洛尔治疗冠心病合并心衰效果显著,可以降低TC、TG、LDL-C,升高HDL-C,改善血脂状况和临床症状,提高患者心功能。
Objective:To investigate the clinical efficacy of atorvastatin combined with metoprolol in treatment of coronary heart disease and heart failure.Methods:90 patients with coronary heart disease and heart failure who admitted in the hospital from December 2018 to November 2019 were randomly divided into two groups,with 45 cases in each group.Control group was treated with atorvastatin,and observation group orally took metoprolol based on control group,with 3 months of treatment in two groups.The clinical efficacy,triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),N-terminal pro-brain natriuretic peptide(NT-proBNP)before treatment and after treatment for 3 months were compared between two groups.Results:After treatment,the effective rate of observation group was higher than that of control group;The TC,TG,LDL-C and NT-proBNP in observation group were lower than those in control group,and the HDL-C in observation group was higher than that in control group(P<0.05).Conclusion:Atorvastatin combined with metoprolol in treatment of coronary heart disease and heart failure has significant effects,it can decrease TC,TG,LDL-C and increase HDL-C,improve blood lipid status and clinical symptoms,and improve cardiac function of patients.
作者
邹金荣
ZOU Jinrong(Shangrao People's Hospital,Shangrao Jiangxi 334000,China)
出处
《药品评价》
CAS
2020年第22期62-64,共3页
Drug Evaluation
关键词
冠心病
心力衰竭
阿托伐他汀
美托洛尔
Coronary Heart Disease
Heart Failure
Atorvastatin
Metoprolol
